Protagonist Swings to Loss on Plummeting Collaboration Revenue

Ticker: PTGX · Form: 10-Q · Filed: Nov 6, 2025 · CIK: 1377121

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Clinical Trials, Drug Development, Revenue Decline, Net Loss, Collaboration Agreements

Related Tickers: PTGX, JNJ, TAK

TL;DR

**PTGX's massive revenue drop and net loss signal a tough road ahead, despite pipeline progress; watch those collaboration milestones closely.**

AI Summary

Protagonist Therapeutics, Inc. (PTGX) reported a significant decline in revenue and a net loss for the nine months ended September 30, 2025, primarily due to a substantial decrease in license and collaboration revenue. Revenue plummeted to $38.579 million for the nine months ended September 30, 2025, a drastic 85.4% decrease from $263.795 million in the same period of 2024. This led to a net loss of $85.765 million for the nine months ended September 30, 2025, compared to a net income of $143.514 million in the prior year. Research and development expenses increased by 9.4% to $112.932 million, reflecting continued investment in its pipeline, including rusfertide's Phase 3 development and Breakthrough Therapy designation by the FDA in August 2025. The company's cash, cash equivalents, and marketable securities stood at $678.8 million as of September 30, 2025, providing liquidity despite the accumulated deficit of $426.3 million. The NDA submission for icotrokinra by Janssen in July 2025 and the MAA submission in Europe in September 2025 represent key strategic milestones for the company's partnered programs.

Why It Matters

This significant revenue drop and net loss are critical for investors, signaling a shift from profitability to a burn rate, largely due to the timing of collaboration payments. While the company maintains a strong cash position of $678.8 million, the reliance on milestone payments from partners like Janssen and Takeda introduces revenue volatility. For employees, continued R&D investment in rusfertide and other programs offers stability, but the overall financial performance will be closely watched. Customers, particularly patients awaiting icotrokinra and rusfertide, will be impacted by the successful progression and commercialization of these drugs, which are now in advanced stages. In the competitive biopharmaceutical market, consistent revenue streams are vital for sustained innovation and market positioning, making the future success of partnered assets paramount for PTGX.

Risk Assessment

Risk Level: medium — The company reported a net loss of $85.765 million for the nine months ended September 30, 2025, a significant reversal from the $143.514 million net income in the prior year. This is primarily driven by an 85.4% decrease in license and collaboration revenue from $263.795 million to $38.579 million, indicating high reliance on unpredictable milestone payments and potential future capital needs despite $678.8 million in cash and marketable securities.

Analyst Insight

Investors should closely monitor upcoming clinical trial results and regulatory approvals for icotrokinra and rusfertide, as these milestones are crucial for future collaboration revenue. Given the substantial net loss and revenue volatility, consider this a speculative investment until a more consistent revenue stream from commercialized products or new collaboration agreements is established.

Financial Highlights

revenue
$38,579,000
total Assets
$701,688,000
total Debt
$56,251,000
net Income
$(85,765,000)
eps
$(1.35)
cash Position
$678,800,000
revenue Growth
-85.4%

Revenue Breakdown

SegmentRevenueGrowth
License and collaboration revenue$38,579,000-85.4%

Key Numbers

Key Players & Entities

FAQ

What caused Protagonist Therapeutics' significant revenue decline in Q3 2025?

Protagonist Therapeutics' license and collaboration revenue decreased by 85.4% to $38.579 million for the nine months ended September 30, 2025, from $263.795 million in the prior year. This substantial drop is likely due to the timing of milestone payments from its collaboration partners, rather than a decrease in ongoing program activity.

What is the current status of Protagonist Therapeutics' lead drug candidate, icotrokinra?

Icotrokinra, licensed to Janssen Biotech, Inc., had a New Drug Application (NDA) submitted to the U.S. FDA in July 2025 for moderate-to-severe plaque psoriasis. Additionally, a Marketing Authorisation Application was submitted to the European Medicines Agency in September 2025 for the same indication.

How has Protagonist Therapeutics' net income changed from 2024 to 2025?

Protagonist Therapeutics reported a net loss of $85.765 million for the nine months ended September 30, 2025. This is a significant change from the net income of $143.514 million reported for the same period in 2024.

What is the significance of rusfertide's Breakthrough Therapy designation for Protagonist Therapeutics?

Rusfertide, being co-developed with Takeda Pharmaceuticals, Inc., was granted Breakthrough Therapy designation by the FDA in August 2025 for the treatment of erythrocytosis in patients with polycythemia vera. This designation can expedite the development and review process for drugs intended to treat serious conditions.

What are the primary risks to Protagonist Therapeutics' financial stability?

The primary risks include the company's reliance on milestone payments from collaboration agreements, which can be highly variable, as evidenced by the 85.4% revenue decline. The company also has an accumulated deficit of $426.3 million, indicating a history of losses, and may need to raise additional capital for its long-range business plan.

How much cash and marketable securities does Protagonist Therapeutics have as of September 30, 2025?

As of September 30, 2025, Protagonist Therapeutics had cash, cash equivalents, and marketable securities totaling $678.8 million. This provides a substantial liquidity buffer despite the recent net loss.

What are Protagonist Therapeutics' other pipeline programs besides icotrokinra and rusfertide?

Beyond its lead programs, Protagonist Therapeutics has several other drug discovery and development programs. These include the IL-17 oral peptide antagonist PN-881, the obesity triple agonist peptide PN-477, and an oral hepcidin program.

How did Protagonist Therapeutics' research and development expenses change in the first nine months of 2025?

Research and development expenses for Protagonist Therapeutics increased to $112.932 million for the nine months ended September 30, 2025, up from $103.224 million in the same period of 2024. This 9.4% increase reflects continued investment in its clinical programs.

What is Protagonist Therapeutics' strategy for funding its operations?

Since its initial public offering in August 2016, Protagonist Therapeutics has primarily financed its operations through proceeds from offerings of common stock and payments received under license and collaboration agreements. The company acknowledges it may need to raise additional capital in the future.

What is polycythemia vera, the rare blood disorder rusfertide is being developed for?

Polycythemia vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells, leading to increased blood viscosity and a higher risk of blood clots. Rusfertide, an injectable mimetic of the natural hormone hepcidin, is being developed to treat erythrocytosis in patients with PV.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Protagonist Therapeutics rely heavily on successful drug development and strategic partnerships to generate revenue. The competitive landscape is intense, with many companies vying for market share in therapeutic areas like hematology and immunology.

Regulatory Implications

Protagonist Therapeutics faces significant regulatory risks associated with drug development and approval processes. The FDA's Breakthrough Therapy designation for rusfertide is a positive signal, but the company's success also hinges on the regulatory approvals of partnered drugs like icotrokinra by agencies such as the FDA and EMA.

What Investors Should Do

  1. Monitor R&D spending and pipeline progress
  2. Analyze revenue drivers and partnership performance
  3. Assess cash burn rate and future financing needs

Key Dates

Glossary

License and collaboration revenue
Revenue generated from agreements where Protagonist Therapeutics licenses its technology or collaborates with other companies on drug development and commercialization. (This is the primary source of revenue that has seen a dramatic decline, significantly impacting the company's overall financial performance.)
Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (Indicates the company's history of operating at a loss, which can be a concern for investors regarding long-term profitability and financial stability.)
Breakthrough Therapy designation
A designation by the FDA that expedites the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. (This designation for rusfertide suggests strong potential and could lead to a faster path to market, a key positive development for the company's pipeline.)
NDA submission
New Drug Application, a formal request to the FDA to review a new drug for marketing approval in the United States. (Represents a critical step in the drug development process for icotrokinra, signaling progress towards potential commercialization.)
MAA submission
Marketing Authorisation Application, the application submitted to the European Medicines Agency (EMA) for approval to market a medicine in the European Union. (Indicates progress in gaining regulatory approval in a major international market for icotrokinra.)

Year-Over-Year Comparison

Protagonist Therapeutics has seen a dramatic shift in its financial performance compared to the prior year. Revenue has plummeted by 85.4% for the nine months ended September 30, 2025, primarily due to a sharp decrease in license and collaboration revenue, leading to a net loss of $85.765 million versus a substantial net income of $143.514 million in the same period of 2024. While research and development expenses have increased by 9.4% to $112.932 million, reflecting ongoing pipeline investment, the overall financial picture is bearish due to the significant revenue drop and increased net loss.

Filing Stats: 4,309 words · 17 min read · ~14 pages · Grade level 18 · Accepted 2025-11-06 16:52:09

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 40 Item 3. Defaults Upon Senior Securities 40 Item 4. Mine Safety Disclosures 40 Item 5. Other Information 40 Item 6. Exhibits 40

SIGNATURES

SIGNATURES 42 Table of Contents

– FINANCIAL INFORMATION

PART I. – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS PROTAGONIST THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share data) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 113,713 $ 97,249 Marketable securities 462,404 321,664 Receivable from collaboration partner 583 165,000 Prepaid expenses and other current assets 9,724 7,728 Total current assets 586,424 591,641 Marketable securities - noncurrent 102,703 140,252 Property and equipment, net 4,100 3,190 Restricted cash - noncurrent 287 225 Operating lease right-of-use asset 8,174 9,417 Total assets $ 701,688 $ 744,725 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 5,646 $ 1,615 Accrued expenses and other payables 22,868 23,693 Income taxes payable — 2,689 Deferred revenue 14,200 18,891 Operating lease liability 2,228 510 Total current liabilities 44,942 47,398 Deferred revenue - noncurrent 2,788 11,676 Operating lease liability - noncurrent 8,521 10,356 Total liabilities 56,251 69,430 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding — — Common stock, $ 0.00001 par value, 180,000,000 shares authorized; 62,447,102 and 61,035,139 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 1 1 Additional paid-in capital 1,071,198 1,015,898 Accumulated other comprehensive income (loss) 525 ( 82 ) Accumulated deficit ( 426,287 ) ( 340,522 ) Total stockholders' equity 645,437 675,295 Total liabilities and stockholders' equity $ 701,688 $ 744,725 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 Table of Contents PROTAGONIST THERAPEUTICS, INC. Condensed Consolida

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing